Style | Citing Format |
---|---|
MLA | Ghane Y, et al.. "Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review." Lasers in Medical Science, vol. 39, no. 1, 2024, pp. -. |
APA | Ghane Y, Heidari N, Hosseini SA, Heidari A, Pishraftsabet H, Eghbali S, Goodarzi A (2024). Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review. Lasers in Medical Science, 39(1), -. |
Chicago | Ghane Y, Heidari N, Hosseini SA, Heidari A, Pishraftsabet H, Eghbali S, Goodarzi A. "Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review." Lasers in Medical Science 39, no. 1 (2024): -. |
Harvard | Ghane Y et al. (2024) 'Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review', Lasers in Medical Science, 39(1), pp. -. |
Vancouver | Ghane Y, Heidari N, Hosseini SA, Heidari A, Pishraftsabet H, Eghbali S, et al.. Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review. Lasers in Medical Science. 2024;39(1):-. |
BibTex | @article{ author = {Ghane Y and Heidari N and Hosseini SA and Heidari A and Pishraftsabet H and Eghbali S and Goodarzi A}, title = {Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review}, journal = {Lasers in Medical Science}, volume = {39}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Ghane Y AU - Heidari N AU - Hosseini SA AU - Heidari A AU - Pishraftsabet H AU - Eghbali S AU - Goodarzi A TI - Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo-Acanthosis Nigricans Treatment: A Systematic Review JO - Lasers in Medical Science VL - 39 IS - 1 SP - EP - PY - 2024 ER - |